Results 151 to 160 of about 1,359 (188)
Some of the next articles are maybe not open access.
Journal of Intensive Care Medicine
BACKGROUND Persistent vasopressor requirements are a common reason for delayed liberation from the intensive care unit (ICU) and adjunct oral agents are sometimes used to hasten time to vasopressor discontinuation.
Andrew J. Webb+10 more
semanticscholar +1 more source
BACKGROUND Persistent vasopressor requirements are a common reason for delayed liberation from the intensive care unit (ICU) and adjunct oral agents are sometimes used to hasten time to vasopressor discontinuation.
Andrew J. Webb+10 more
semanticscholar +1 more source
Droxidopa for Symptomatic Neurogenic Hypotension
Cardiology in Review, 2017Droxidopa is a first-in-class, orally available, synthetic amino acid precursor of norepinephrine that received accelerated Food and Drug Administration approval in February 2014 after Orphan Drug status for a debilitating condition known as symptomatic neurogenic orthostatic hypotension.
openaire +3 more sources
Simultaneous determination of droxidopa and carbidopa using a carbon nanotubes paste electrode
Sensors and Actuators B: Chemical, 2013Abstract A novel carbon paste electrode modified with carbon nanotube and 5-amino-2’-ethyl -biphenyl-2-ol (5AEB) was fabricated. The electrochemical study of the modified electrode, as well as its efficiency for electrocatalytic oxidation of droxidopa and carbidopa, is described. Cyclic voltammetry was used to investigate the redox properties of this
Somayeh Tajik, Somayeh Tajik, M Cepeda
exaly +3 more sources
Droxidopa approved for neurogenic orthostatic hypotension
American Journal of Health-System Pharmacy, 2014Droxidopa, a synthetic amino acid precursor of norepinephrine, has been approved as oral therapy for the treatment of neurogenic orthostatic hypotension, FDA and Chelsea Therapeutics announced on February 18.
openaire +2 more sources
Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases
Expert Opinion on Pharmacotherapy, 2019L-threo-3,4-dihydroxyphenylserine (droxidopa), a pro-drug metabolized to norepinephrine in nerve endings and other tissues, has been commercially available in Japan since 1989 for treating orthostatic hypotension symptoms in Parkinson's disease (PD) patients with a Hoehn & Yahr stage III rating, as well as patients with Multiple System Atrophy (MSA ...
Santiago Pérez-Lloret+3 more
openaire +4 more sources
L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension
Clinical Autonomic Research, 2008Neurogenic orthostatic hypotension is a cardinal feature of generalised autonomic failure and commonly is the presenting sign in patients with primary autonomic failure. Orthostatic hypotension can result in considerable morbidity and even mortality and is a major management problem in disorders such as pure autonomic failure, multiple system atrophy ...
Christopher J. Mathias+1 more
openaire +3 more sources
Exploration and evaluation of adverse event signals of droxidopa based on the FAERS database.
Expert Opinion on Drug SafetyBACKGROUND This study aims to utilize the FDA's Adverse Event Reporting System (FAERS) for data analysis to explore the potential adverse events associated with Droxidopa in real-world settings, thereby providing reference information for clinical ...
Xinnan Chen+3 more
semanticscholar +1 more source
Droxidopa: A Review of Its Use in Symptomatic Neurogenic Orthostatic Hypotension
Drugs, 2015The norepinephrine prodrug droxidopa (NORTHERA™) is approved in the US for the treatment of orthostatic dizziness, lightheadedness, or the 'feeling that you are about to black out' in adults with symptomatic neurogenic orthostatic hypotension associated with primary autonomic failure (e.g.
exaly +4 more sources
DBH deficiency in an elderly patient: efficacy and safety of chronic droxidopa
Clinical Autonomic Research, 2010We describe the effects of chronic droxidopa in a patient with Dopamine beta-hydroxylase deficiency diagnosed at the age of 73. Investigations were performed to assess sympathetic activity (MIBG scintigraphy, catecholamines) and cardiovascular droxidopa safety.
P. Massabuau+11 more
openaire +3 more sources